ATR and cancer: Since DNA damage checkpoint kinases ATR and WEE1 are among key regulators of DNA damage/repair pathways26, we then estimated the IC50 for WEE1 (AZD1775) and ATR (AZD6738) inhibitors based on promising early clinical trial results in other cancer types27–31.